Product Specials

Manuscript Highlights Phase 2 Development of St. Renatus’ Nasal Anesthetic Technology

Posted on August 27, 2012

Fort Collins, Colo. – August 24, 2012– The August 2012 edition of The Journal of The American Dental Association (JADA) includes a nine‐page manuscript describing a phase of development of St. Renatus’ needle‐free intranasal dental anesthetic.

The manuscript is titled “The cardiovascular effects and pharmacokinetics of intranasal tetracaine plus oxymetazoline: Preliminary findings.” It includes data, graphs, methods, statistical analyses, results and conclusion of the Phase 2 Pharmacokinetics (PK) study that was completed in November 2010 at the University of Pennsylvania. This study determined the safety of the investigative drug in adults.

Dr. Elliott Hersh, the Associate Professor of Pharmacology Oral & Maxillofacial Surgery at the University of Pennsylvania and the Principal Investigator for the PK study, submitted the manuscript earlier this year. He co‐wrote with Helen Giannakopoulos, DDS, MD; Lawrence M. Levin, DMD, MD; Joli C. Chou, DMD, MD; Anthony T. Cacek, PharmD; Matthew Hutcheson, MS; Stacey A. Secreto, CCRC; and Paul A. Moore, DMD, PhD, MPH.

The JADA is a source of information for the American Dental Association (ADA), which has more than 155,000 members. The journal is published monthly and includes articles and manuscripts on research, clinical information, dental industry news, assessments of practice building and legal topics, continuing education and other programs.

“It’s a privilege to be included in such a prestigious journal, read by thousands of dentists and other industry professionals around the world,” said St. Renatus’ CEO Steve Merrick. “St. Renatus hopes everyone in the dental profession reads about the development of our investigative drug.”

St. Renatus has just begun Adult Phase 3 clinical trials at Jean Brown Research in Salt Lake City, Utah, and will begin shortly at the University of Maryland School Of Dentistry. It will further test the wide scale safety and efficacy studies of the nasal mist on an expected total of 380 adult subjects at various sites in the coming months. The subjects will all undergo needed dental procedures. St. Renatus expects to complete Adult Phase 3 clinical trials by the end of 2012.

For more on the manuscript in this month’s The JADA, please visit http://jada.ada.org. For more information about St. Renatus, please visit www.st.renatus.com.